Luiza Doro

Clinical utility of upfront liquid biopsy in non-small cell lung cancer in the community setting

Luiza Doro, Gonca Ozcan, Emily F. Collier, James Vredenburgh

us (code pays fourni par la source)

Objective predictors of financial toxicity in oncology

Aleksei Bazhenov, Luiza Doro, David Michael O'Sullivan, Alvaro G. Menendez

BACKGROUND: Current financial toxicity (FT) screening tools rely on patient-reported risk factors. Underrepresented populations may not be forthcoming about FT fears due to cultural concerns of treatment withholding or migratory repercussions, if applicable. Identifying objective risk factors, such as social determinants of …

us (code pays fourni par la source)

Clinical utility of upfront liquid biopsy in non-small cell lung cancer in the community setting.

Luiza Doro, Gonca Ozcan, James J. Vredenburgh, Emily F. Collier

316 Background: Molecular diagnosis of advanced non-small cell lung cancer (NSCLC) is critical to guide therapeutic decisions. Blood next generation sequencing (NGS) allows for non-invasive screening for targetable genetic abnormalities. Many studies have validated using the liquid biopsies to screen for resistant …

us (code pays fourni par la source)

Identifying objective risk factors of financial toxicity in patients with cancer.

Aleksei Bazhenov, Luiza Doro, David Michael O'Sullivan, Alvaro G. Menendez

e24116 Background: Current financial toxicity (FT) screening tools rely on patient-reported risk factors (RF)1. Underrepresented populations may not be forthcoming about FT fears due to cultural concerns of treatment withholding or migratory repercussions, if applicable1–4. Identifying objective RF, such as social determinants …

us (code pays fourni par la source)

Second-Line Treatment of Metastatic Renal Cell Carcinoma: Systematic Review and Network Meta-Analysis

Pablo Moura Barrios, Pedro Castilhos de Freitas Crivelaro, Carolina Gomes da Silveira Cauduro, André Poisl Fay et autres